抗CD20与二甲基 fumarate作为儿科多发性硬化症的第一线治疗:一项回顾性队列研究
Masoud Etemadifar1, Aryana Ramezani1, Pantea Miralaei1
1School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Neuropediatrics
|August 14, 2025
概括
双甲基烟酸 (DMF) 和抗CD20疗法有效降低了儿科多发性硬化症 (MS) 的复发率. 这两种治疗方法在本研究中都显示出类似的疗效和安全性,为POMS管理提供了宝贵的见解.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 对儿科发病多发性硬化症 (POMS) 的第一线治疗缺乏共识.
- 双甲基烟酸 (DMF) 和抗CD20疗法正在成为儿童MS的有利选择.
研究的目的:
- 为了比较DMF与抗CD20疗法的有效性和安全性,作为POMS的第一线治疗.
- 评估治疗结果,包括复发率和残疾进展.
主要方法:
- 从2012年7月到2022年7月进行的回顾性队列研究.
- 包括39名18岁以下的儿科MS患者,接受DMF或抗CD20药物的治疗,随访至少12个月.
- 分析了年度复发率 (ARR) 和扩展残疾状况得分 (EDSS),以及不良事件.
主要成果:
- 在DMF和抗CD20组中,从基线到随访期间,中位数ARR显著降低 (p < 0.0001).
- 在这两组中都没有观察到EDSS中位数的显著变化.
- 17/23名DMF患者和12/16名抗CD20患者在12个月后没有复发;两组之间没有发现有效性结果的显著差异.
结论:
- 两种DMF和抗CD20疗法都显著降低了POMS中的ARR和疾病活性,并具有可接受的安全性.
- 在这个队列中,DMF和抗CD20疗法之间没有观察到有效性的显著差异.
- 需要进一步的临床试验来证实这些发现.
更多相关视频
09:41Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
2.0K
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.8K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)